suven life sciences' pashamylaram facility successfully completes usfda inspection .: "targeted cgrp small molecule antagonists for acute migraine therapy.".
schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals.".
august 2, 2017. +1 dailymail